Rocket Lab SEC Filings

This PRE 14A is the preliminary proxy statement for Rocket Lab's 2026 Annual Meeting on May 20, 2026. It proposes electing one Class II director (Edward H. Frank), ratifying Deloitte as auditors for 2026, advisory approval of 2025 NEO compensation, and approving a subsidiary merger to eliminate the pass-through voting provision in wholly-owned sub Rocket Lab USA, Inc.'s charter added during 2025 holding company reorganization. Investors should note the governance simplification and routine items; prior attempt to remove provision failed supermajority threshold despite strong support.

Arjun Kampani, SVP & General Counsel, acquired 77,189 restricted stock units (RSUs) at $0 on March 24, 2026, increasing direct holdings to 475,177 shares. This is a standard equity compensation grant under the 2021 Stock Option and Incentive Plan. Signal is neutral as it is routine compensation, not a discretionary purchase.

Adam C. Spice, Chief Financial Officer, disposed of 1,558 shares of common stock via gift on 03/20/2026. He now holds 1,295,266 shares directly. Neutral signal as gifts are non-monetary and do not indicate market sentiment.

This 424B5 is a prospectus supplement for an at-the-market (ATM) offering of up to $1 billion in common stock through multiple sales agents, including forward transactions. Rocket Lab is terminating its prior $750 million sales agreement after selling $749.4 million. Investors should note potential dilution from ongoing equity raises to fund growth amid Neutron delays.

Rocket Lab entered into an Equity Distribution Agreement on March 17, 2026, with multiple sales agents to offer and sell up to $1 billion of common stock from time to time, either directly or via forward transactions. No immediate proceeds are received; sales occur at market prices with commissions up to 2%. The program uses an existing shelf registration statement.

Rocket Lab announced its 2026 annual meeting of stockholders will be held on May 20, 2026. Due to the meeting date changing by more than 30 days from the 2025 annual meeting, the deadline for Rule 14a-8 stockholder proposals and Bylaw director nominations is March 22, 2026. No financial impact is associated with this announcement.

Merline Saintil, a Director at Rocket Lab USA Inc., sold 18,126 shares of common stock on 03/06/2026 at a weighted average price of $75.04. This reduced her direct holdings to 261,903 shares. The discretionary sale without a 10b5-1 plan indicates a moderately bearish signal.

Rocket Lab director Merline Saintil has filed Form 144 to sell 18,126 shares of common stock on or around March 6, 2026, with an aggregate market value of $1,360,171.41. The shares stem from restricted stock units that vested on June 14, 2023, as compensation from the issuer. In the past three months, Saintil sold 37,500 shares for approximately $2.7 million.

Peter Beck, CEO and Director of Rocket Lab USA, sold a total of 18,857 common shares on 03/02/2026 through multiple sell-to-cover transactions to satisfy tax withholding on vesting RSUs under a Rule 10b5-1 plan. These sales were automatic and non-discretionary. The signal is neutral as it reflects standard compensation-related activity rather than voluntary selling.

Arjun Kampani, SVP & General Counsel, sold 52,472 shares of RKLB common stock on March 2-4, 2026, through sell-to-cover transactions for tax withholding on RSU vesting and automatic sales under a Rule 10b5-1 plan. Total proceeds approximately $3.7M at weighted average prices ranging $66.83-$74.09. Signal is neutral given the pre-planned nature.